

Noninsulin-Dependent Diabetes Mellitus 1. The Journal of Clinical Endocrinology & Metabolism 1998; 83: 744–750.

16. Ahren B, Pratley R, Soubt M et al. Clinical Measures of Islet Function: Usefulness to Characterize Defects in Diabetes. Current Diabetes Reviews 2008; 4: 129–145.

17. Matthews DR, Hosker JP, Rudenski AS et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412–419.

18. Wallace TM, Levy JC, Matthews DR. Use and Abuse of HOMA Modeling. Diabetes Care 2004; 27: 1487–1495.

19. Levy JC, Matthews DR, Hermans MP. Correct Homeostasis Model Assessment (HOMA) Evaluation Uses the Computer Program. Diabetes Care 1998; 21: 2191–2192.

20. Katz A, Nambi SS, Mather K, et al. Quantitative Insulin Sensitivity Check Index: A Simple, Accurate Method for Assessing Insulin Sensitivity In Humans. The Journal of Clinical Endocrinology & Metabolism 2000; 85: 2402–2410.

21. Chen H, Sullivan G, Quon MJ. Assessing the Predictive Accuracy of QUICKI as a Surrogate Index for Insulin Sensitivity Using a Calibration Model. Diabetes 2005; 54: 1914–1925.

22. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999; 22: 1462–1470.

23. Lorenzo C, Haffner SM, Stančáková A et al. Fasting and OGTT-derived Measures of Insulin Resistance as Compared With the Euglycemic-Hyperinsulinemic Clamp in Nondiabetic Finnish Offspring of Type 2 Diabetic Individuals. The Journal of Clinical Endocrinology & Metabolism 2015; 100: 544–550.

24. Xiang AH, Watanabe RM, Buchanan TA. HOMA and Matsuda indices of insulin sensitivity: poor correlation with minimal model-based estimates of insulin sensitivity in longitudinal settings. Diabetologia 2014; 57: 334–338.

25. Pacini G, Mari A. Methods for clinical assessment of insulin sensitivity and β -cell function. Best Practice & Research Clinical Endocrinology & Metabolism 2003; 17: 305–322.

26. Bruinstroop E, Meyer L, Brouwer CB et al. Retrospective Analysis of an Insulin-to-Liraglutide Switch in Patients with Type 2 Diabetes Mellitus. Diabetes Therapy 2018; 9: 1369–1375.

27. Kawata T, Kanamori A, Kubota A et al. Is a Switch From Insulin Therapy to Liraglutide Possible in Japanese Type 2 Diabetes Mellitus Patients? Journal of Clinical Medicine Research 2014; E744.

28. Iwao T, Sakai K, Sata M. Postprandial serum C-peptide is a useful parameter in the prediction of successful switching to liraglutide monotherapy from complex insulin therapy in Japanese patients with type 2 diabetes. Journal of Diabetes and its Complications 2013; 27: 87–91.

29. Davis SN, Johns D, Maggs D et al. Exploring the Substitution of Exenatide for Insulin in Patients With Type 2 Diabetes Treated With Insulin in Combination With Oral Antidiabetic Agents. Diabetes Care 2007; 30: 2767–2772.

30. Araki H, Tanaka Y, Yoshida S et al. Oral glucose-stimulated serum C-peptide predicts successful switching from insulin therapy to liraglutide monotherapy in Japanese patients with type 2 diabetes and renal impairment. Journal of Diabetes Investigation 2014; 5: 435–441.

31. Aron-Wisnewsky J, Sokolovska N, Liu Y et al. The advanced-DiaRem score improves prediction of diabetes remission 1 year post-Roux-en-Y gastric bypass. Diabetologia 2017; 60: 1892–1902.

32. Dicker D, Golan R, Aron-Wisnewsky J et al. Prediction of Long-Term Diabetes Remission After RYGB, Sleeve Gastrectomy, and Adjustable Gastric Banding Using DiaRem and Advanced-DiaRem Scores. Obesity Surgery 2019; 29: 796–804.

33. Steven S, Hollingsworth Kg, Al-Mrabeh A et al. Very Low-Calorie Diet and 6 Months of Weight Stability in Type 2 Diabetes: Pathophysiological Changes in Responders and Nonresponders. Diabetes Care 2016; 39: 808–815.



FAKULTNÍ
NEMOCNICE
U SV. ANNY
V BRNĚ



Pozvánka

XXV. postgraduální diabetologický seminář Brno 2020

Akce je pořádána pod záštitou ČDS a je zařazena do systému kontinuálního vzdělávání lékařů. Věříme, že přijmete naše pozvání k aktivní účasti na tomto semináři, který pro Vás bude přínosem z odborného i společenského hlediska.

Těšíme se na setkání s Vámi.

20. - 21. 3. 2020
hotel Holiday Inn
Brno

DIABETES

Přihlášky a informace na **www.diabrno.cz**

www.diabrno.cz | e-mail: info@diabrno.cz | tel.: 775 553 611

Seminář organizuje: Lion Media, s.r.o. | www.lionmedia.cz